优酷

People with HIV at higher risk of COVID reinfection: CDC_我的网站

一 |     People with HIV are at increased risk of being reinfected with the virus that causes COVID-19, according to new federal data.Researchers from the Centers for Disease Control and Prevention and the Chicago Department of Public Health followed adult residents in Chicago from their first reported infection from March 2020 through the end of May 2022, according to the report published Wednesday by the CDC.The team compared COVID test laboratory data and COVID vaccine administration data to Chicago's Enhanced HIV/AIDS Reporting System.About 5% experienced reinfection among more than 453,000 Chicago residents who tested positive for the virus.Rates of reinfection were higher among people with HIV (6.7%) than among people without HIV (5.2%).People with HIV are more likely to have completed a primary COVID vaccine series plus a booster before their reinfection -- 31.8% versus 27% for those without HIV.Reinfection rates were consistently higher throughout the pandemic for people with HIV and were highest during the original omicron variant phase, according to the report."Understanding if persons with HIV have a higher risk for SARS-CoV-2 reinfection may help tailor future COVID-19 public health guidance," the authors wrote. "[Persons with HIV] should follow the recommended COVID-19 vaccine schedule, including booster doses, to avoid SARS-CoV-2 reinfections."Those who were reinfected were more likely to be male, older and Black or African American compared to those without HIV, the study found.People with HIV were also less likely to have been unvaccinated at the time of their first infection compared to people without HIV.The report notes the findings are a reminder about the risks of reinfection for those who are immunocompromised.HIV can weaken the immune system, infecting and destroying CD4 cells, which causes the white blood cell count to drop and compromises the immune system.This means that people with HIV are susceptible to COVID infection especially those who are not on antiretroviral therapy (ART).ART is a combination of drugs that suppresses a person's viral load until HIV Is virtually undetectable. The ability of ART to control viral replication has been shown to greatly improve immune system function, studies show."Evaluating the association between HIV infection and SARS-CoV-2 reinfections using surveillance data can help strengthen public health recommendations including the need for extra doses as part of a primary series, booster doses of vaccine, and optimized ART in [persons with HIV]," the authors wrote. "Tailored guidance and prevention messaging for [persons with HIV] can help reduce the elevated risk we identified in this analysis and limit continued SARS-CoV-2 transmission."。    　　中新社北京8月25日电 (记者 刘文文)中国商务部新闻发言人、副部长兼国际贸易谈判副代表凌激25日在北京表示，中国在共建“一带一路”国家设立境外企业2.2万家。　　凌激在当日国新办举行的发布会上表示，近年来中国对外投资发展引人注目。

二 | 一方面，对外投资规模稳居全球前列，并呈现出多元化的投资趋势。2025年，中国对外投资流量是2135.8亿美元，比上年增长11.1%，对外投资存量已达到3.4万亿美元，连续9年保持在全球前三，占全球投资的比重增加到7.4%。　　他说，对外投资的行业覆盖了国民经济的18个行业门类，过去传统的投资主要集中在租赁和商务服务、批发零售、制造业和金融这四个领域，近年来逐步向绿色低碳、数字经济和绿色矿产等领域稳步拓展。　　另一方面，互利共赢成效显著。截止到2025年底，中国在境外设立的企业有5.8万家，遍布189个国家和地区，为东道国年均创造就业岗位超过200万个。凌激说，中国企业在海外积极融入全球和区域经济，不仅带动了自身发展，提升了竞争力，也为东道国产业发展和全球产供链作出了贡献。

三 | 　　此外，“一带一路”合作成果丰硕。凌激表示，2025年中国企业对共建“一带一路”国家的直接投资达到460.5亿美元，占当年对外投资流量的21.6%。中国在共建“一带一路”国家设立的境外企业是2.2万家，直接投资存量4072.5亿美元。

四 | “一带一路”为中国企业对外投资搭建了广阔平台，实现了“共商、共建、共享”的良好格局。

五 |

Current article:http://u9y.feishuozhuangkeqi.cyou/list_h6q/0l66fv.html

Published on:16:57:53